Santarus Company Profile (NASDAQ:SNTS)

About Santarus (NASDAQ:SNTS)

Santarus logoSantarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SNTS
  • CUSIP: 80281730
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $23,462.00
  • 200 Day Moving Avg: $23,012.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 19.85
  • P/E Growth: 0
  • Dividend Yield: 1.0%

Frequently Asked Questions for Santarus (NASDAQ:SNTS)

What is Santarus' stock symbol?

Santarus trades on the NASDAQ under the ticker symbol "SNTS."

Who are some of Santarus' key competitors?

How do I buy Santarus stock?

Shares of Santarus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Santarus' stock price today?

One share of Santarus stock can currently be purchased for approximately $31.96.

MarketBeat Community Rating for Santarus (NASDAQ SNTS)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Santarus (NASDAQ:SNTS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Santarus (NASDAQ:SNTS)
No equities research coverage for this company has been tracked by


Earnings History for Santarus (NASDAQ:SNTS)
Earnings by Quarter for Santarus (NASDAQ:SNTS)
Earnings History by Quarter for Santarus (NASDAQ SNTS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2013Q313$0.33$0.45$94.45 million$98.79 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.18$0.94$82.90 million$89.40 millionViewN/AView Earnings Details
5/6/2013Q1 2013$0.15$0.25$74.70 million$79.44 millionViewN/AView Earnings Details
3/4/2013Q4 2012$0.01$0.08$62.02 million$70.20 millionViewN/AView Earnings Details
11/7/2012Q312$0.10$0.13$53.04 million$54.70 millionViewN/AView Earnings Details
8/7/2012$0.08$0.05ViewN/AView Earnings Details
5/8/2012($0.01)$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Santarus (NASDAQ:SNTS)
Current Year EPS Consensus Estimate: $1.37 EPS
Next Year EPS Consensus Estimate: $1.61 EPS


Dividend History for Santarus (NASDAQ:SNTS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Santarus (NASDAQ:SNTS)
Insider Trades by Quarter for Santarus (NASDAQ:SNTS)
Insider Trades by Quarter for Santarus (NASDAQ:SNTS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2013Gerald ProehlCEOSell56,643$31.95$1,809,743.85View SEC Filing  
12/16/2013Kent SnyderDirectorSell7,500$31.95$239,625.00View SEC Filing  
12/9/2013Meules Julie DeVPSell15,165$31.95$484,521.75View SEC Filing  
11/15/2013Kent SnyderDirectorSell7,500$32.01$240,075.00View SEC Filing  
11/11/2013Meules Julie DeVPSell15,165$31.94$484,370.10View SEC Filing  
10/15/2013Gerald ProehlCEOSell50,000$22.32$1,116,000.00View SEC Filing  
10/15/2013Kent SnyderDirectorSell7,500$22.31$167,325.00View SEC Filing  
10/10/2013Debra CrawfordCFOSell16,614$21.90$363,846.60View SEC Filing  
10/9/2013Meules Julie DeVPSell15,165$21.14$320,588.10View SEC Filing  
10/8/2013Maria Bedoya-ToroSVPSell10,000$21.39$213,900.00View SEC Filing  
10/7/2013Carey FoxSVPSell17,100$21.91$374,661.00View SEC Filing  
10/1/2013William C DenbyVPSell24,450$23.03$563,083.50View SEC Filing  
9/16/2013Gerald ProehlCEOSell50,000$22.19$1,109,500.00View SEC Filing  
9/16/2013Kent SnyderDirectorSell7,500$22.18$166,350.00View SEC Filing  
9/10/2013Debra P CrawfordCFOSell19,000$22.38$425,220.00View SEC Filing  
9/9/2013Carey J FoxSVPSell17,100$22.19$379,449.00View SEC Filing  
9/9/2013Meules Julie A DeVPSell15,165$21.90$332,113.50View SEC Filing  
9/5/2013Michael D StepSVPSell30,303$23.17$702,120.51View SEC Filing  
9/3/2013William DenbyVPSell24,450$22.43$548,413.50View SEC Filing  
8/15/2013Kent SnyderDirectorSell7,500$25.89$194,175.00View SEC Filing  
8/12/2013Debra CrawfordCFOSell19,000$26.40$501,600.00View SEC Filing  
8/9/2013Meules Julie DeVPSell15,165$26.55$402,630.75View SEC Filing  
8/8/2013Maria Bedoya-ToroSVPSell10,000$27.35$273,500.00View SEC Filing  
8/7/2013Carey FoxSVPSell17,100$27.36$467,856.00View SEC Filing  
8/2/2013E David Ballard IISVPSell9,000$24.96$224,640.00View SEC Filing  
8/1/2013William C DenbyVPSell24,450$24.77$605,626.50View SEC Filing  
7/15/2013Kent SnyderDirectorSell35,000$25.36$887,600.00View SEC Filing  
7/10/2013Debra P CrawfordCFOSell19,000$23.17$440,230.00View SEC Filing  
7/9/2013Meules Julie A DeVPSell15,165$23.52$356,680.80View SEC Filing  
7/8/2013Maria E Bedoya-ToroSVPSell10,000$23.34$233,400.00View SEC Filing  
7/5/2013Michael D StepSVPSell30,301$21.76$659,349.76View SEC Filing  
7/3/2013Warren E HallVPSell28,749$21.54$619,253.46View SEC Filing  
7/2/2013E David Ballard IISVPSell9,000$21.45$193,050.00View SEC Filing  
7/1/2013William C DenbyVPSell25,050$21.56$540,078.00View SEC Filing  
6/10/2013Debra P CrawfordCFOSell19,000$21.45$407,550.00View SEC Filing  
6/10/2013Maria E Bedoya-ToroSVPSell10,000$21.57$215,700.00View SEC Filing  
6/10/2013Meules Julie A DeVPSell15,165$21.67$328,625.55View SEC Filing  
6/7/2013Carey J FoxSVPSell17,100$20.54$351,234.00View SEC Filing  
6/3/2013Daniel D BurgessDirectorSell8,000$21.34$170,720.00View SEC Filing  
6/3/2013E David Ballard IISVPSell9,000$21.34$192,060.00View SEC Filing  
6/3/2013William C DenbyVPSell24,450$21.46$524,697.00View SEC Filing  
5/15/2013Cha Alessandro DellaDirectorSell16,500$21.33$351,945.00View SEC Filing  
5/15/2013Technologies Ltd CosmoMajor ShareholderSell4,887,500$17.68$86,411,000.00View SEC Filing  
5/14/2013Michael E HermanDirectorSell25,000$20.77$519,250.00View SEC Filing  
5/10/2013Debra P CrawfordCFOSell18,643$19.27$359,250.61View SEC Filing  
5/9/2013Meules Julie A DeVPSell15,165$20.10$304,816.50View SEC Filing  
5/8/2013Maria E Bedoya-ToroSVPSell10,000$20.53$205,300.00View SEC Filing  
5/1/2013Daniel D BurgessDirectorSell8,000$17.88$143,040.00View SEC Filing  
5/1/2013William C DenbyVPSell24,450$17.90$437,655.00View SEC Filing  
4/10/2013Debra P CrawfordCFOSell19,000$16.82$319,580.00View SEC Filing  
12/18/2012Ted W LoveDirectorBuy185,000$10.88$2,012,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Santarus (NASDAQ:SNTS)
Latest Headlines for Santarus (NASDAQ:SNTS)
No headlines for this company have been tracked by



Santarus (SNTS) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff